ProMIS reports positive Phase 1a data for PMN310 in Alzheimer's

ProMIS Neurosciences Inc.

PMN310 well-tolerated across four SAD cohorts (2.5-20 mg/kg); no treatment-emergent SAEs.
CSF levels dose-proportional at days 3 and 29; lowest dose >100-fold molar excess over expected oligomers.
CSF half-life ~25 days, supportive of monthly dosing.
Company plans to initiate Phase 1b in Alzheimer's patients in H2 2024.
Full dataset to be presented at a medical meeting in H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.